查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1969268

登革热疫苗市场：依疫苗类型、剂型、年龄层、通路、最终用户划分，全球预测，2026-2032年

Dengue Vaccine Market by Vaccine Type, Dosage Form, Age Group, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，登革热疫苗市场价值将达到 5.8039 亿美元，到 2026 年将成长至 6.3593 亿美元，到 2032 年将达到 10.9116 亿美元，复合年增长率为 9.43%。

主要市场统计数据
基准年 2025 580,390,000 美元
预计年份：2026年 6.3593亿美元
预测年份 2032 1,091,160,000 美元
复合年增长率 (%) 9.43%

简要概述不断变化的科学、监管和供应动态，这些动态正在重塑公共卫生和商业性相关人员。

近年来，在免疫学进步、公共卫生紧迫性意识增强以及监管方式不断演变的推动下，登革热疫苗的研发在全球加速。临床试验计画从早期阶段发展到成熟的III期临床试验和社区登记阶段，而安全性问题和上市后监测体系的加强也促使政策制定者更密切地关注疫苗研发。同时，生产平台的改进和对血清学风险的更深入了解也重新定义了临床应用情境和目标族群。

科学进步、监管调整和分销创新如何汇聚，重新定义登革热疫苗引进和分销的战略路径。

登革热疫苗领域正经历一场变革，其驱动力包括科学突破、监管进步以及公众期望的转变。疫苗平台技术的进步使得候选疫苗能够涵盖更广泛的血清型并改变其反应原性，促使监管机构采用差异化的核准途径，将血清抑制和风险缓解措施纳入考虑。伴随这些技术变革，相关人员的期望也不断成熟。政策制定者现在要求更强有力的核准后安全性数据，而公众则期望获得透明的风险沟通和可衡量的公共卫生影响。

评估关税变化和贸易政策调整如何重塑登革热疫苗生态系统内的供应链韧性、生产决策和筹资策略。

关税和贸易壁垒的实施将对疫苗研发商和经销商的商业经济效益和策略决策产生重大影响。针对原料、专用设备和包装组件的进口关税及相关课税会导致供应週期延长和采购成本增加。当关税与严格的低温运输要求或来自单一来源且难以在区域内替代的投入品同时出现时，这些影响会被放大。在这种情况下，製造商和买家可能需要承担更高的到岸成本或调整供应路线，以确保供应的可及性和可靠性。

关键的细分洞察，将疫苗特性、供应链、终端用户接受能力、管理物流和特定年龄层的需求纳入可操作的部署策略。

细分市场主导策略至关重要，因为不同细分市场的产品性能、分销需求、终端用户期望、接种物流以及特定年龄层的疫苗接种率各不相同，这些都会影响疫苗的引入和供应模式。基于疫苗类型的分析需要区分活病毒疫苗候选产品和重组次单元製剂。这些疫苗在免疫抗原性原性、禁忌症和生产基础设施方面存在差异，而这些差异会影响医护人员的咨询和上市后安全监测。基于通路的分析表明，透过医院药房、线上药房和零售药房供应的疫苗面临不同的物流要求、法律规范和患者参与方式，因此需要製定相应的分销策略。

区域协调观点：美洲、欧洲、中东、非洲和亚太地区的流行病学、监管实践和交付能力的协调一致。

区域差异是决定登革热疫苗策略成功与否的关键因素，因为流行病学、监管体系、基础设施和支付方的预期都存在显着差异。在美洲，需要采取综合方法，结合地方政府健康服务、学校分发和积极的社区参与，以应对公共免疫规划和都市区感染率问题。这将有助于消除以往的疫苗接种犹豫，并确保不同都市区人口的疫苗接种率。同时，在欧洲、中东和非洲，法规环境各不相同，一些地区强调严格的核准前证据，而另一些地区则优先考虑透过紧急使用授权或有条件核准途径获得疫苗。适应性强的监管合作和区域特定的安全数据可以加快疫苗在适宜的国家计画中的部署。

深入了解决定登革热疫苗研发公司竞争优势和供应韧性的企业策略、製造合作伙伴关係和监管应对措施。

登革热疫苗领域的企业策略体现了平台专长、临床产品组合规划和策略合作的综合运用。成熟的製药公司利用其现有的监管经验和生产规模，为后期候选疫苗的上市许可和复杂的核准后承诺提供支援。新兴生物技术公司和专业疫苗研发企业通常与大型生产商合作，以推动差异化疫苗结构和规模化生产，从而实现全球分销。合约研发生产机构（CDMO）在帮助疫苗申办者加速供应方面发挥着至关重要的促进者，它们提供填充和包装能力、分析支援以及低温运输包装解决方案。

为高阶管理层提供协调证据产生、供应链韧性、与监管机构对话以及相关人员参与以实现有效疫苗部署的实用建议。

行业领导者应采取多管齐下的方法来推动永续的疫苗接种计划，平衡临床证据的积累、供应链的韧性、与监管机构的合作以及建立相关人员的信心。优先投资于健全的核准后安全监测系统和透明的传播策略，积极解决有关血清学状态和不利事件的担忧。同时，应拓展製造地和供应商之间的关係，以降低贸易中断带来的风险，并促进区域供应。尽可能加强本地能力，包括透过技术转移协议等方式。

为了支持策略决策，我们采用高度透明的调查方法，该方法整合了与关键相关人员的访谈、系统的二手文献综述、透过三角测量获得的安全性和实施数据以及基于情境的风险分析。

本报告的分析整合了第一手和第二手调查方法，旨在为决策者建立具有合法性和可操作性的证据基础。第一手研究包括对临床医生、供应链专家、监管官员和公共卫生政策制定者进行结构化访谈，并辅以咨询委员会的咨询，将试验资料和现场经验置于具体情境中进行解读。第二手研究则涉及对同行评审的临床文献、监管文件、安全监测报告和公共卫生指南进行系统性回顾，以验证产品特性和实施过程中遇到的挑战。

结论是平衡的，既强调了登革热疫苗接种的潜力，又承认了在实证要求、物流和协作实施方面需要采取的实际措施，以对公共卫生产生积极影响。

登革热疫苗已从理论上的可能性转变为许多公共卫生系统和相关人员的首要行动，但要充分发挥其潜力，需要科学、政策和物流的严格协调。疫苗结构的进步和监管经验的累积为保护弱势群体创造了新的机会。然而，实现广泛且公平的疫苗取得取决于谨慎的产品选择、健全的安全监测和供应链的前瞻性。疫苗配方的选择、与通路的兼容性以及针对不同年龄层的策略，将决定这些疫苗对人群的益处程度。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：登革热疫苗市场：依疫苗类型划分

  • 减毒活疫苗
  • 可重构子次单元

第九章：登革热疫苗市场：以剂型划分

  • 多管瓶小瓶
  • 预填充式注射器
  • 单剂量管瓶

第十章：登革热疫苗市场：依年龄组别划分

  • 青春期
  • 成人
  • 儿童

第十一章：登革热疫苗市场：依通路划分

  • 医院药房
  • 网路药房
  • 零售药房

第十二章：登革热疫苗市场：依最终用户划分

  • 诊所
  • 医院
  • 研究机构

第十三章：登革热疫苗市场：按地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章：登革热疫苗市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章：登革热疫苗市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国：登革热疫苗市场

第十七章 中国：登革热疫苗市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Biological E. Limited
  • GeneOne Life Science
  • GlaxoSmithKline（GSK）plc
  • Johnson & Johnson Services, Inc.
  • Medigen Vaccine Biologics
  • Merck & Co. Inc.
  • Novartis AG
  • Sanofi Pasteur
  • Serum Institute of India
  • Sun Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company
  • Vabiotech
Product Code: MRR-535C62918799

The Dengue Vaccine Market was valued at USD 580.39 million in 2025 and is projected to grow to USD 635.93 million in 2026, with a CAGR of 9.43%, reaching USD 1,091.16 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 580.39 million
Estimated Year [2026] USD 635.93 million
Forecast Year [2032] USD 1,091.16 million
CAGR (%) 9.43%

A concise orientation to the evolving scientific, regulatory, and delivery dynamics that are reshaping dengue vaccine priorities across public health and commercial stakeholders

The global trajectory of dengue vaccine development has accelerated in recent years, driven by advances in immunology, renewed public health urgency, and evolving regulatory approaches. Clinical programs that were once nascent have matured into phase III trials and regional registrations, while safety concerns and post-implementation surveillance have sharpened policymaker scrutiny. Concurrently, improvements in manufacturing platforms and a deeper understanding of serostatus-related risks have reshaped clinical positioning and target populations.

As dengue continues to exert a heavy burden across tropical and subtropical regions, health systems and private stakeholders are re-evaluating prevention strategies. Vaccination is increasingly seen as a complement to vector control and diagnostic strengthening, rather than a standalone solution. This shift requires more nuanced commercial and public health planning to align product profiles with the epidemiology of serotypes, age cohorts, and local healthcare delivery models.

Consequently, decision-makers are placing higher value on granular evidence that links vaccine performance to real-world implementation realities. Translating clinical trial data into policy-relevant guidance necessitates robust post-marketing safety monitoring, adaptive immunization schedules where appropriate, and coordinated stakeholder engagement to build confidence among clinicians and communities. The introduction of new vaccine candidates has therefore prompted a strategic re-think across manufacturers, regulators, and payers about how to prioritize access, distribution, and long-term surveillance in a rapidly evolving landscape.

How scientific advances, regulatory recalibration, and distribution innovation are converging to redefine strategic pathways for dengue vaccine implementation and uptake

The dengue vaccine landscape is undergoing transformative shifts driven by scientific breakthroughs, regulatory evolution, and changing public expectations. Advances in vaccine platforms have enabled candidates with broader serotype coverage and altered reactogenicity profiles, prompting regulators to apply differentiated approval pathways that weigh serostatus and risk mitigation measures. Parallel to these technical shifts, stakeholder expectations have matured: policymakers now demand stronger post-authorization safety data, and communities expect transparent risk communication and measurable public health impact.

Commercial strategy has also adapted to these changes. Manufacturers are prioritizing scalable production processes, cold-chain innovations, and regional manufacturing partnerships to support faster, more resilient supply. Health systems are exploring targeted immunization approaches that align vaccine indications with local epidemiology, such as age-stratified programs or serostatus-informed deployment where feasible. Meanwhile, integration with diagnostic and surveillance systems has become a priority so that vaccination efforts can be monitored and optimized in near real time.

These dynamics have produced a more complex but also more opportunity-rich environment. Investors and strategic planners must now balance the technical promise of new vaccine constructs against practical considerations of delivery, acceptance, and regulatory constraints. Success will depend on multi-stakeholder collaboration, evidence-driven communication, and agile commercialization models that can respond to emerging safety and effectiveness data as implementation scales.

Assessing how tariff shifts and trade policy adjustments are reshaping supply chain resilience, production decisions, and procurement strategies in the dengue vaccine ecosystem

The imposition of tariffs and trade barriers can materially affect the operational economics and strategic decisions of vaccine developers and distributors. When import duties or ancillary levies target raw materials, specialized equipment, or packaging components, supply timelines can lengthen and procurement costs can rise. These effects are amplified when tariffs intersect with stringent cold-chain requirements or with single-source inputs that lack easy regional substitutes. In such circumstances, manufacturers and purchasers may need to absorb higher landed costs or reconfigure supply routes to preserve access and reliability.

Beyond direct cost implications, tariff regimes have downstream consequences for manufacturing location choices and partnership models. Firms may recalibrate investment to favor facilities in tariff-exempt jurisdictions or accelerate technology transfers to local manufacturers to mitigate recurring tariff exposure. This reorientation has implications for workforce development, quality oversight, and regulatory coordination across multiple authorities. Importantly, tariffs can also affect the economics of different dosage forms; for example, single-dose prefilled syringes may carry distinct import profiles compared with multi-dose vials, shaping product selection and procurement strategy for national immunization programs.

Policy responses and commercial mitigations typically include pursuing tariff exemptions for essential public health goods, advocating for harmonized trade treatments for biologics, and exploring duty-drawback or bonded warehousing solutions to ease cash flow pressure. Strategic planning should therefore incorporate scenario analyses of tariff policy trajectories, supply chain redundancy planning, and stakeholder engagement to preserve access while ensuring programmatic sustainability.

Critical segmentation insights that align vaccine attributes, delivery channels, end-user capacities, dosage logistics, and age-specific needs to practical deployment strategies

Segment-driven strategy is essential because product performance, distribution needs, end-user expectations, dosage logistics, and age-targeted uptake each vary in ways that influence adoption and delivery models. Based on Vaccine Type, analysis must differentiate live attenuated candidates from recombinant subunit constructs because their immunogenicity profiles, contraindications, and manufacturing footprints differ; these distinctions influence provider counseling and post-marketing safety monitoring. Based on Distribution Channel, vaccines supplied through hospital pharmacies, online pharmacies, and retail pharmacies will encounter distinct logistics requirements, regulatory oversight, and patient engagement practices, so distribution strategy must be tailored accordingly.

Based on End User, clinics, hospitals, and research institutes have varying capacities for cold-chain maintenance, patient screening, and adverse event reporting, which will shape training, support, and surveillance investments. Based on Dosage Form, multi-dose vials, prefilled syringes, and single-dose vials each present trade-offs between wastage, cold-storage footprint, and point-of-care convenience; procurement teams should weigh these factors against clinic throughput and waste-management capacities. Based on Age Group, strategies for adolescents, adults, and children must reflect immunization schedules, consent frameworks, and communication approaches that differ across caregivers, schools, and workplaces.

Integrating these segmentation lenses enables stakeholders to prioritize product portfolios, tailor distribution partnerships, and design targeted education campaigns. Combining product-specific attributes with channel and end-user realities will improve alignment between clinical potential and real-world performance, thereby supporting more efficient deployment and higher uptake.

Regionally calibrated perspectives that reconcile epidemiology, regulatory practice, and delivery capabilities across the Americas, Europe Middle East & Africa, and Asia-Pacific

Regional differentiation remains a defining feature of successful dengue vaccine strategies because epidemiology, regulatory systems, infrastructure, and payer expectations vary substantially. In the Americas, public immunization programs and urban transmission settings require approaches that integrate municipal health services, school-based delivery, and active community engagement to address historical vaccine hesitancy and to ensure coverage across diverse urban and rural populations. In contrast, Europe, Middle East & Africa presents a heterogeneous regulatory mosaic where some jurisdictions focus on stringent pre-authorization evidence while others prioritize access through emergency or conditional pathways; adaptive regulatory engagement and region-specific safety data can accelerate uptake in receptive national programs.

Asia-Pacific contains many of the highest-burden areas and therefore presents both urgent need and rapid policy interest in vaccination. Implementation in this region often necessitates coordination with large-scale national immunization programs, complex public-private partnerships, and robust surveillance networks to monitor serotype dynamics. Across all regions, considerations such as local manufacturing capacity, cold-chain robustness, and supplier diversity influence whether procurement favors long-established global suppliers or regional manufacturing collaborations.

Successful regional strategies blend clinical evidence with pragmatic delivery planning, regulatory dialogue, and stakeholder communication tailored to local sensitivities. A one-size-fits-all approach is unlikely to perform; instead, regionally calibrated plans that respect local health system capacities, policy priorities, and cultural contexts will yield more sustainable outcomes.

Insight into how corporate strategies, manufacturing partnerships, and regulatory positioning are determining competitive advantage and supply resilience among dengue vaccine developers

Company strategies in the dengue vaccine area reflect a mix of platform specialization, clinical portfolio decisions, and strategic partnerships. Established pharmaceutical firms have leveraged existing regulatory experience and manufacturing scale to shepherd late-stage candidates and to support complex post-authorization commitments. Emerging biotech organizations and specialty vaccine developers are advancing differentiated constructs and often partner with larger manufacturers for scale-up and global distribution. Contract development and manufacturing organizations have become key enablers, providing fill-finish capacity, analytical support, and cold-chain packaging solutions that allow vaccine sponsors to accelerate availability.

Competitive positioning is increasingly influenced by demonstrated real-world performance, regulatory clarity on serostatus-related use, and the ability to offer integrated delivery solutions that reduce programmatic friction. Firms that invest early in local regulatory engagement, epidemiologic partnerships, and community outreach programs are more likely to achieve broader acceptance. Strategic alliances between global developers and regional manufacturers can unlock supply resilience while satisfying local-content considerations and regulatory requirements.

Intellectual property strategies, licensing agreements, and manufacturing partnerships will continue to shape who can scale production rapidly and who can adapt products to regional needs. For purchasers and partners, the most relevant differentiators will be demonstrated safety in diverse populations, logistical compatibility with recipient health systems, and the flexibility to support targeted deployment models.

Actionable recommendations for senior executives to align evidence generation, supply resilience, regulatory dialogue, and stakeholder engagement for effective vaccine rollout

Industry leaders should adopt a multi-pronged approach that balances clinical evidence generation, supply-chain resilience, regulatory engagement, and stakeholder trust-building to advance sustainable vaccination programs. Prioritize investments in robust post-authorization safety surveillance systems and transparent communication strategies that proactively address concerns about serostatus and adverse events. Simultaneously, diversify manufacturing and supplier relationships to reduce vulnerability to trade disruptions and to facilitate regional supply, including technology-transfer arrangements where possible to strengthen local capacity.

Engage regulators early and consistently to clarify intended use populations, labeling strategies, and required post-market commitments so that approvals can align with implementation timelines. Tailor distribution models to the realities of target delivery channels; for example, align product presentation and cold-chain needs with the capacities of hospital pharmacies, retail outlets, or community clinics. Design age-specific outreach campaigns that reflect caregiver concerns for children, school-based delivery opportunities for adolescents, and workplace or primary-care pathways for adults.

Finally, advocate for policy frameworks that recognize vaccines as critical public health goods, including tariff exemptions, streamlined import procedures, and financing mechanisms that reduce barriers to access. By integrating scientific rigor with pragmatic operational planning and stakeholder engagement, industry leaders can improve the likelihood of successful and equitable vaccine rollouts.

A transparent methodology integrating primary stakeholder interviews, systematic secondary review, triangulated safety and implementation data, and scenario-based risk analysis to inform strategic decision-making

The analysis underpinning this report integrates primary and secondary research techniques designed to produce a defensible, actionable evidence base for decision-makers. Primary inputs include structured interviews with clinicians, supply-chain specialists, regulatory affairs leaders, and public health policymakers, supplemented by advisory-board consultations that contextualize trial data and field experience. Secondary research encompassed a systematic review of peer-reviewed clinical literature, regulatory documents, safety surveillance reports, and public health guidance to triangulate product profiles and implementation challenges.

Analytical rigor was reinforced by cross-validation of clinical endpoints reported in pivotal studies with pharmacovigilance findings and programmatic observations from regions with active use. Risk assessments evaluated supply-chain fragility, tariff exposure, and cold-chain constraints, while scenario planning explored alternative distribution and manufacturing configurations. Quality assurance measures included source verification, methodologic transparency, and iterative review by subject-matter experts to ensure that interpretations are grounded in available evidence and real-world operational realities.

Limitations of the methodology are acknowledged: evolving clinical data and regulatory determinations can change the evidence base, and local health-system heterogeneity can affect transferability of certain implementation recommendations. To mitigate these limits, the approach emphasizes modular updates and stakeholder validation workshops that refine insights as new data emerge.

A balanced conclusion highlighting the promise of dengue vaccination tied to pragmatic requirements for evidence, logistics, and collaborative implementation to achieve public health impact

Dengue vaccination has moved from a theoretical possibility to an operational priority for many public health systems and commercial stakeholders, but realizing its full potential requires disciplined alignment of science, policy, and logistics. Advances in vaccine constructs and growing regulatory experience have created new opportunities to protect vulnerable populations, yet the path to broad, equitable access is contingent on careful product selection, robust safety monitoring, and supply-chain foresight. Attention to dosage form selection, distribution channel compatibility, and age-targeted strategies will determine how effectively these vaccines translate into population-level benefit.

Policymakers and industry must collaborate to resolve practical barriers such as trade frictions, cold-chain limitations, and heterogeneous regulatory requirements. When these elements are addressed in a coordinated manner, vaccination programs can amplify the impact of vector-control and diagnostic efforts, creating more durable reductions in dengue burden. Ultimately, stakeholder confidence will hinge on transparent communication, measurable implementation outcomes, and adaptive programs that respond to emerging evidence.

The evolving dengue vaccine ecosystem presents meaningful opportunities for public health gains, provided that strategic investments in evidence generation, supply resilience, and stakeholder partnership are sustained and effectively executed.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Dengue Vaccine Market, by Vaccine Type

  • 8.1. Live Attenuated
  • 8.2. Recombinant Subunit

9. Dengue Vaccine Market, by Dosage Form

  • 9.1. Multi-Dose Vial
  • 9.2. Prefilled Syringe
  • 9.3. Single-Dose Vial

10. Dengue Vaccine Market, by Age Group

  • 10.1. Adolescents
  • 10.2. Adults
  • 10.3. Children

11. Dengue Vaccine Market, by Distribution Channel

  • 11.1. Hospital Pharmacies
  • 11.2. Online Pharmacies
  • 11.3. Retail Pharmacies

12. Dengue Vaccine Market, by End User

  • 12.1. Clinics
  • 12.2. Hospitals
  • 12.3. Research Institutes

13. Dengue Vaccine Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Dengue Vaccine Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Dengue Vaccine Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Dengue Vaccine Market

17. China Dengue Vaccine Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Biological E. Limited
  • 18.6. GeneOne Life Science
  • 18.7. GlaxoSmithKline (GSK) plc
  • 18.8. Johnson & Johnson Services, Inc.
  • 18.9. Medigen Vaccine Biologics
  • 18.10. Merck & Co. Inc.
  • 18.11. Novartis AG
  • 18.12. Sanofi Pasteur
  • 18.13. Serum Institute of India
  • 18.14. Sun Pharmaceutical Industries Ltd.
  • 18.15. Takeda Pharmaceutical Company
  • 18.16. Vabiotech

LIST OF FIGURES

  • FIGURE 1. GLOBAL DENGUE VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL DENGUE VACCINE MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL DENGUE VACCINE MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL DENGUE VACCINE MARKET SIZE, BY VACCINE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL DENGUE VACCINE MARKET SIZE, BY DOSAGE FORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL DENGUE VACCINE MARKET SIZE, BY AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL DENGUE VACCINE MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL DENGUE VACCINE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL DENGUE VACCINE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL DENGUE VACCINE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES DENGUE VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA DENGUE VACCINE MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL DENGUE VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL DENGUE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL DENGUE VACCINE MARKET SIZE, BY LIVE ATTENUATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL DENGUE VACCINE MARKET SIZE, BY LIVE ATTENUATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL DENGUE VACCINE MARKET SIZE, BY LIVE ATTENUATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL DENGUE VACCINE MARKET SIZE, BY RECOMBINANT SUBUNIT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL DENGUE VACCINE MARKET SIZE, BY RECOMBINANT SUBUNIT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL DENGUE VACCINE MARKET SIZE, BY RECOMBINANT SUBUNIT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL DENGUE VACCINE MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL DENGUE VACCINE MARKET SIZE, BY MULTI-DOSE VIAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL DENGUE VACCINE MARKET SIZE, BY MULTI-DOSE VIAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL DENGUE VACCINE MARKET SIZE, BY MULTI-DOSE VIAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL DENGUE VACCINE MARKET SIZE, BY PREFILLED SYRINGE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL DENGUE VACCINE MARKET SIZE, BY PREFILLED SYRINGE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL DENGUE VACCINE MARKET SIZE, BY PREFILLED SYRINGE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL DENGUE VACCINE MARKET SIZE, BY SINGLE-DOSE VIAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL DENGUE VACCINE MARKET SIZE, BY SINGLE-DOSE VIAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL DENGUE VACCINE MARKET SIZE, BY SINGLE-DOSE VIAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL DENGUE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL DENGUE VACCINE MARKET SIZE, BY ADOLESCENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL DENGUE VACCINE MARKET SIZE, BY ADOLESCENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL DENGUE VACCINE MARKET SIZE, BY ADOLESCENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL DENGUE VACCINE MARKET SIZE, BY ADULTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL DENGUE VACCINE MARKET SIZE, BY ADULTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL DENGUE VACCINE MARKET SIZE, BY ADULTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL DENGUE VACCINE MARKET SIZE, BY CHILDREN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL DENGUE VACCINE MARKET SIZE, BY CHILDREN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL DENGUE VACCINE MARKET SIZE, BY CHILDREN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL DENGUE VACCINE MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL DENGUE VACCINE MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL DENGUE VACCINE MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL DENGUE VACCINE MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL DENGUE VACCINE MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL DENGUE VACCINE MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL DENGUE VACCINE MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL DENGUE VACCINE MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL DENGUE VACCINE MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL DENGUE VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL DENGUE VACCINE MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL DENGUE VACCINE MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL DENGUE VACCINE MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL DENGUE VACCINE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL DENGUE VACCINE MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL DENGUE VACCINE MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL DENGUE VACCINE MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL DENGUE VACCINE MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL DENGUE VACCINE MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL DENGUE VACCINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. AMERICAS DENGUE VACCINE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 51. AMERICAS DENGUE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 52. AMERICAS DENGUE VACCINE MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 53. AMERICAS DENGUE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. AMERICAS DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 55. AMERICAS DENGUE VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 56. NORTH AMERICA DENGUE VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. NORTH AMERICA DENGUE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 58. NORTH AMERICA DENGUE VACCINE MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 59. NORTH AMERICA DENGUE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. NORTH AMERICA DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 61. NORTH AMERICA DENGUE VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 62. LATIN AMERICA DENGUE VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. LATIN AMERICA DENGUE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 64. LATIN AMERICA DENGUE VACCINE MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 65. LATIN AMERICA DENGUE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. LATIN AMERICA DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 67. LATIN AMERICA DENGUE VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 68. EUROPE, MIDDLE EAST & AFRICA DENGUE VACCINE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 69. EUROPE, MIDDLE EAST & AFRICA DENGUE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 70. EUROPE, MIDDLE EAST & AFRICA DENGUE VACCINE MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 71. EUROPE, MIDDLE EAST & AFRICA DENGUE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. EUROPE, MIDDLE EAST & AFRICA DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 73. EUROPE, MIDDLE EAST & AFRICA DENGUE VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 74. EUROPE DENGUE VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. EUROPE DENGUE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 76. EUROPE DENGUE VACCINE MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 77. EUROPE DENGUE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. EUROPE DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPE DENGUE VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 80. MIDDLE EAST DENGUE VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. MIDDLE EAST DENGUE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. MIDDLE EAST DENGUE VACCINE MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 83. MIDDLE EAST DENGUE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. MIDDLE EAST DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 85. MIDDLE EAST DENGUE VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 86. AFRICA DENGUE VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. AFRICA DENGUE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 88. AFRICA DENGUE VACCINE MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 89. AFRICA DENGUE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. AFRICA DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 91. AFRICA DENGUE VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 92. ASIA-PACIFIC DENGUE VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC DENGUE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC DENGUE VACCINE MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC DENGUE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC DENGUE VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL DENGUE VACCINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. ASEAN DENGUE VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. ASEAN DENGUE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 101. ASEAN DENGUE VACCINE MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 102. ASEAN DENGUE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. ASEAN DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 104. ASEAN DENGUE VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 105. GCC DENGUE VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GCC DENGUE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. GCC DENGUE VACCINE MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 108. GCC DENGUE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GCC DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 110. GCC DENGUE VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPEAN UNION DENGUE VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPEAN UNION DENGUE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPEAN UNION DENGUE VACCINE MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPEAN UNION DENGUE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPEAN UNION DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPEAN UNION DENGUE VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 117. BRICS DENGUE VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. BRICS DENGUE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. BRICS DENGUE VACCINE MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 120. BRICS DENGUE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 121. BRICS DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 122. BRICS DENGUE VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 123. G7 DENGUE VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. G7 DENGUE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. G7 DENGUE VACCINE MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 126. G7 DENGUE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 127. G7 DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 128. G7 DENGUE VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 129. NATO DENGUE VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. NATO DENGUE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. NATO DENGUE VACCINE MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 132. NATO DENGUE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 133. NATO DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 134. NATO DENGUE VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL DENGUE VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. UNITED STATES DENGUE VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 137. UNITED STATES DENGUE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. UNITED STATES DENGUE VACCINE MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 139. UNITED STATES DENGUE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 140. UNITED STATES DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 141. UNITED STATES DENGUE VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 142. CHINA DENGUE VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 143. CHINA DENGUE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. CHINA DENGUE VACCINE MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 145. CHINA DENGUE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 146. CHINA DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 147. CHINA DENGUE VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)